Tilray Brands is aggressively pursuing growth in international medical cannabis markets, but this operational strategy is currently clashing with a pessimistic outlook from equity analysts. The company recently announced its largest product launch to date in Australia, aiming to significantly increase its footprint in that nation’s regulated sector.
Financial Performance: A Mixed Picture
The company’s latest quarterly results present a complex financial landscape. Total revenue reached a record $217.5 million. Furthermore, Tilray achieved a notable turnaround in its balance sheet, moving from a net debt position to holding net cash of approximately $27.4 million.
However, these top-line gains are shadowed by profitability concerns. Gross margins contracted to 26%, a decline attributed primarily to shifts in the sales mix. Additionally, the adjusted free cash flow remained negative. This combination of rising revenue alongside margin compression is fueling investor skepticism about the path to sustainable profitability.
Market and Analyst Sentiment Turns Cautious
The capital market’s reaction has been decidedly cool. Tilray shares are currently trading around $6.73, having lost roughly 23% of their value since the start of 2026. From a technical analysis perspective, the stock remains under pressure, consistently trading below its key short-term and long-term moving averages.
Should investors sell immediately? Or is it worth buying Tilray?
This bearish trend is reflected in recent analyst actions. Research firm Roth Mkm dramatically slashed its price target for Tilray by half, reducing it from $20.00 to $10.00. Earlier in March, Wall Street Zen downgraded the stock to a “Sell” rating. While there are pockets of institutional interest—such as J.W. Cole Advisors, which substantially increased its stake—the broader consensus remains cautious, with an average “Hold” rating.
Strategic Focus on Medical Cannabis Growth
The centerpiece of Tilray’s strategy is its global medical cannabis business. The Australian launch involves introducing a wide range of new product formats under the Redecan and Good Supply brands, including flowers, extracts, vapes, and pastilles. Rajnish Ohri, Tilray’s Head of International, identifies the Australian market as a pivotal growth engine for the coming years.
This international medical segment is showing strength, with sales surging 36% year-over-year in the second quarter of fiscal 2026. The company now supplies patients, hospitals, and pharmacies across 20 countries on five continents. The Australian expansion is viewed as another strategic step to reduce reliance on any single market and to solidify its global leadership position in the medical cannabis sector.
The coming months will be critical for Tilray. As the company continues to streamline its operations, the market awaits clear evidence that its international growth can translate into sustained, positive cash flow and support healthier margins.
Ad
Tilray Stock: Buy or Sell?! New Tilray Analysis from March 20 delivers the answer:
The latest Tilray figures speak for themselves: Urgent action needed for Tilray investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 20.
Tilray: Buy or sell? Read more here...
